News

Younger adults (aged 20 – 40 years) with OSA were 3 times more likely to experience any type of CVD event than those without OSA.

The novel potassium-competitive acid blocker now boasts 3 FDA approvals across erosive and non-erosive GERD, expanding the treatment armamentarium for patients and clinicians.

Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.

Vonoprazan (Voquezna), the first major innovation in GERD treatment in more than 30 years, is now FDA-approved for both erosive and non-erosive GERD.

Adalimumab-adbm is now available at a 92% discount from the reference drug list price through GoodRx.

OTX-TKI remained generally well-tolerated in patients with moderately severe to severe NPDR across 48 weeks of the Phase 1 trial.

Announced on July 18, 2024, the FDA approval for heartburn relief associated with non-erosive GERD is based on the phase 3 PHALCON-NERD-301 trial.

Katherine Talcott, MD describes a posthoc analysis of the GATHER trials showing how imaging biomarkers of photoreceptor structure predict GA growth.

Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.

These data suggest that risk of developing psoriatic arthritis among patients with different variants of psoriasis vary based on race and sex as well.

A new study showed the efficiency and speed of a new AI model for a heart scan.

The cross-sectional analysis found Medicaid nonexpansion status, fibrosis, and sobriety restrictions negatively impacted annual rates of DAA prescription fills.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.

Health literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.

In this interview, Rosmarin discussed the results of a new post-hoc analysis of the TRuE-V1 and TRuE-V2 studies on treating younger vitiligo patients with ruxolitinib cream.

A study with real-world data showed certolizumab pegol was effective in treating psoriasis a year later, with a probability of 1-year persistence at approximately 85%.

Findings highlight an increased risk of diabetes, MASLD, and cardiovascular disease in patients with PCOS, with risk varying by PCOS phenotype.

Phase 2a results demonstrated the efficacy and safety of orally administered CU06-1004 and may warrant further clinical studies in DME.

SGLT2 inhibitors may provide a favorable impact on the risk of sight-threatening diabetic retinal complications compared with other glucose-lowering therapies.

We break down 5 top trials to keep an eye on at ASRS 2024, taking place in Stockholm, Sweden from July 17 to 20, 2024.

Awareness of these data may allow for dermatologists to better care for patients with anogenital pruritus as well as their families.

Levinthal explains recent advances in the understanding of CVS and how the AGA clinical practice update reflects new information about its diagnosis and management.

A study found omega-3 supplements and a Mediterranean diet improved acne severity and quality of life in patients without prescription meds.

In this analysis, investigators highlighted the results of treating psoriasis with deucravacitinib in the phase 3 POETYK PSO-1 and PSO-2 trials.

A new study confirms GLP-1RAs do not increase the risk for suicidal thoughts or behaviors, aligning with the FDA findings.

A clinical practice update from the American Gastroenterological Association is providing clinicians with an overview of the diagnosis and management of CVS.

This analysis was done to verify the hypothesis that psoriatic arthritis is primarily genetically predetermined and distinct from the condition of psoriasis.

An analysis of data from the NV-HOPE study calls attention to lower rates of HBV and HCV screening among low-income US veterans versus the general US veteran population.